Abstracts tagged "patient preferences and rheumatoid arthritis (RA)"

Abstract Number: 2365 • 2018 ACR/ARHP Annual Meeting
Sex, Language and Age of Disease Onset Impact Illness Perceptions Among RA Patients
Susan J. Bartlett¹, Mariana Useche², Maria Celia Bazan Bardales³, Elizabeth Hazel⁴ and Ines Colmegna⁵, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Rheumatology, McGill University Health Centre, Pointe-Claire, QC, Canada, ⁵The Research Institute of the McGill University Health Centre, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada
Background/Purpose: Patients’ illness perceptions (IP) influence self-management, adherence, and outcomes. Little is known about how cultural background and the lived experiences influence IP among rheumatoid…
Abstract Number: 2779 • 2017 ACR/ARHP Annual Meeting
The Patient Perspective on Bdmard Dose Reduction: A Mixed Methods Study
L.M. Verhoef¹, E.M.H. Selten¹, J.E. Vriezekolk¹, A.J.L. de Jong², F.H.J. van den Hoogen^1,3, A.A. Den Broeder^1,3 and M.E.J.L. Hulscher⁴, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Department of Rheumatology, Rijnstate Arnhem, Arnhem, Netherlands, ³Rheumatology, Radboud university medical centre, Nijmegen, Netherlands, ⁴Radboud Institute for Health Sciences, IQ healthcare, Radboud university medical centre, Nijmegen, Netherlands
Background/Purpose: biological DMARDs (bDMARDs) are effective in the treatment of RA, but are also associated with side-effects and high costs. Dose reduction of bDMARDs, after…
Abstract Number: 1143 • 2014 ACR/ARHP Annual Meeting
Preferences of Biologic Treatment Characteristics Among Rheumatoid Arthritis Patients Who Are Current Biologic Therapy Users
David M. Kern¹, Angela E. Williams², Ozgur Tunceli¹, Bingcao Wu¹, Judy Stephenson¹, Laura Horne³ and Alfred Sackeyfio⁴, ¹HealthCore, Inc., Wilmington, DE, ²MedImmune, LLC, Cambridge, United Kingdom, ³AstraZeneca, Wilmington, DE, ⁴AstraZeneca, Manchester, United Kingdom
Background/Purpose: To identify the most and least important characteristics of rheumatoid arthritis (RA) treatment according to patients currently on biologic therapy. Methods: From the HealthCore…
Abstract Number: 1023 • 2013 ACR/ARHP Annual Meeting
Openness To and Preference For Biologic Therapy Among Patients With Rheumatoid Arthritis Prior To Biologic Initiation: Patient and Prescriber Perspectives
Susan C. Bolge¹, Duncan Brown², Amir Goren³, Roxanne Meyer⁴ and Seth Ginsberg⁵, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Kantar Health, New york, NY, ³Kantar Health, New York, NY, ⁴Janssen Scientific Affairs, LLC, Horsham, NY, ⁵Creaky Joints, New York, NY
Background/Purpose: Currently two modes of administration are available for biologic therapies used to treat rheumatoid arthritis (RA): subcutaneous injection (SQ) and intravenous infusion (IV). Patient…
Abstract Number: 1853 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients’ Experiences of Medication Side Effects and Subsequent Decision Making about Medications
Yomei Shaw¹, Ilinca D. Metes², Susan L. Zickmund³, Dawn McBride², Kelly A. Reckley², Stephen R. Wisniewski⁴, Larry W. Moreland², Mark S. Roberts¹ and Marc C. Levesque², ¹Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA
Background/Purpose: Medication adherence in rheumatoid arthritis (RA) patients can be influenced by their previous experiences with medication side effects. Negative experiences may lead patients to…
Abstract Number: 1578 • 2012 ACR/ARHP Annual Meeting
How Disease Activity Trajectories Affect the Willingness to Change Treatment
Paul Falzer¹ and Liana Fraenkel², ¹Medicine, VA Connecticut Healthcare System, New Haven, CT, ²Medicine, Section of Rheumatology, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT
Background/Purpose: Disease activity (DA) can change markedly over a short period, for a variety of reasons. The changes influence clinical practice and affect the willingness…
Abstract Number: 869 • 2012 ACR/ARHP Annual Meeting
Concepts Which Determine Health in a Positive Way Are Important to People with Rheumatoid Arthritis and Are Covered by Some Patient-Reported Outcome Instruments
Mona Dür¹, Michaela Coenen², Josef S. Smolen³ and Tanja A. Stamm⁴, ¹Internal Medicine III Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Medical lnformatics, Biometry and Epidemiology, Research Unit for Biopsychosocial Health, Ludwig-Maximilians-University, Munich, Germany, ³Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁴Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid arthritis is a chronic autoimmune disease that has a major impact on functioning, health and well-being. Concepts which determine health in a positive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].